{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:58:07Z","timestamp":1790449087152,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07964-6","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:51:24Z","timestamp":1790401884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Letter to the Editor: In-Hospital SGLT-2 Inhibitor Initiation in Acute Heart Failure"],"prefix":"10.1007","author":[{"given":"Muhammad","family":"Owais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maham","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3591-3684","authenticated-orcid":false,"given":"Hafiz M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"7964_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-026-07920-4","author":"HM Ahmed","year":"2026","unstructured":"Ahmed HM, Rehman UU, Owais M. In-Hospital Initiation of SGLT-2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis of Clinical, Decongestion, and Safety Outcomes. Cardiovasc Drugs Ther. 2026. https:\/\/doi.org\/10.1007\/s10557-026-07920-4.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7964_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-026-07953-9","author":"X You","year":"2026","unstructured":"You X, In-Hospital. SGLT-2 Inhibitor Initiation in Acute Heart Failure: Clarifying Event Timing, Mechanisms, and Safety Boundaries. Cardiovasc Drugs Ther. 2026. https:\/\/doi.org\/10.1007\/s10557-026-07953-9.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7964_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijcard.2023.03.002","volume":"379","author":"K Abdel Dayem","year":"2023","unstructured":"Abdel Dayem K, Younis O, Zarif B, Attia S, AbdelSalam A. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients\u2014DACAMI (a randomized controlled clinical trial). Int J Cardiol. 2023;379:9\u201314. https:\/\/doi.org\/10.1016\/j.ijcard.2023.03.002.","journal-title":"Int J Cardiol"},{"issue":"2","key":"7964_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","volume":"3","author":"S James","year":"2024","unstructured":"James S, Erlinge D, Storey RF, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024;3(2):EVIDoa2300286. https:\/\/doi.org\/10.1056\/EVIDoa2300286.","journal-title":"NEJM Evid"},{"issue":"16","key":"7964_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024;390(16):1455\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2314051.","journal-title":"N Engl J Med"},{"key":"7964_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejim.2025.01.014","volume":"135","author":"R Laborante","year":"2025","unstructured":"Laborante R, Paglianiti DA, Bianchini E, et al. Safety and efficacy of early initiation of sodium-glucose co-transporter 2 inhibitors in patients hospitalized for acute heart failure: a meta-analysis of randomized controlled trials. Eur J Intern Med. 2025;135:55\u201363. https:\/\/doi.org\/10.1016\/j.ejim.2025.01.014.","journal-title":"Eur J Intern Med"},{"issue":"13","key":"7964_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens W, Dauw J, Martens P, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2203094.","journal-title":"N Engl J Med"},{"issue":"1","key":"7964_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40264-022-01247-3","volume":"46","author":"DTW Lui","year":"2023","unstructured":"Lui DTW, Wu T, Au ICH, et al. A Population-Based Study of SGLT2 Inhibitor-Associated Postoperative Diabetic Ketoacidosis in Patients with Type 2 Diabetes. Drug Saf. 2023;46(1):53\u201364. https:\/\/doi.org\/10.1007\/s40264-022-01247-3.","journal-title":"Drug Saf"},{"issue":"8","key":"7964_CR9","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/ejhf.2912","volume":"25","author":"S Chatur","year":"2023","unstructured":"Chatur S, Kondo T, Claggett BL, et al. Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. Eur J Heart Fail. 2023;25(8):1364\u201371. https:\/\/doi.org\/10.1002\/ejhf.2912.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07964-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07964-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07964-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:02:13Z","timestamp":1790445733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07964-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":9,"alternative-id":["7964"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07964-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"19 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}